Combination product definition and FDA regulatory requirements

A combination product combines different FDA-regulated constituent types, such as a drug and device. It can be a single entity or meet specific co-packaging or cross-labeling conditions. A prefilled syringe qualifies; a medicine containing two drugs does not qualify merely because it combines drug ingredients. FDA's combination product FAQ explains this distinction.

The classification affects the lead FDA center, manufacturing requirements and postmarketing safety reporting. Those questions have separate answers: lead jurisdiction follows the primary mode of action, while 21 CFR Part 4 covers manufacturing and reporting obligations.

What counts as a combination product?

FDA's definition covers drug-device, biologic-device and drug-biologic combinations, as well as products containing all three constituent types. Combining only devices, or only drugs, does not meet this definition on that basis alone. Searches for "combination drugs" or "combination medicines" can therefore lead to a different regulatory topic. FDA FAQ

The legal definition in §3.2(e) has four numbered limbs. These fit into three broad arrangements:

These examples come from FDA's combination product types page. They illustrate the arrangements, rather than replacing the legal tests.

Cross-labeling needs care. Under the approved-counterpart provision, a separately packaged product must be intended only for use with an approved, individually specified counterpart. Both must be needed for the intended use. Approval must require a change to the counterpart's labeling. A separate limb addresses individually specified investigational products intended only for use together. Two products do not become a combination product simply because a clinician uses them together. 21 CFR §3.2(e)

How FDA assigns the lead center

FDA uses the primary mode of action, or PMOA, to assign primary jurisdiction. This is the mode expected to make the greatest contribution to the product's intended therapeutic effects. It is not a comparison of constituent size, price or visibility. Section 3.2 defines PMOA; §3.4 governs assignment.

If FDA cannot determine PMOA with reasonable certainty, it applies a further assignment process. It first considers which agency component regulates combination products with similar safety and effectiveness questions. Without such products, it considers which component has the most relevant expertise for the most significant questions. Uncertainty does not automatically mean device-center jurisdiction. 21 CFR §3.4

The FDA Office of Combination Products handles classification and assignment issues, intercenter coordination and policy. It does not review marketing applications. The assigned center does that work, with other centers consulted where needed. Lead-center assignment also does not rule out separate applications in appropriate cases. FDA FAQ

For early uncertainty, the Pre-Request for Designation process offers informal, non-binding feedback. It is not a formal designation decision. FDA's revised final Pre-RFD guidance, issued in November 2025, explains how to prepare that request.

What 21 CFR Part 4 requires

Part 4 has two distinct parts. Subpart A addresses current good manufacturing practice, or CGMP. Subpart B addresses postmarketing safety reporting. Reading only the manufacturing provisions leaves out a separate set of obligations. 21 CFR Part 4

Manufacturing requirements follow the constituents

For ordinary drug-device products, the drug constituent brings Parts 210 and 211 into scope, and the device constituent brings Part 820. Section 4.3 also identifies relevant requirements for biological products and other constituent types. 21 CFR §4.3

For single-entity and co-packaged products, §4.4 allows two approaches: full compliance with each applicable CGMP set, or a specified alternative. Under the latter approach, a manufacturer uses a base system and meets identified additional requirements from the other constituent's system. It does not remove those additional quality obligations. Separately manufactured constituents also have facility-specific provisions. 21 CFR §4.4

QMSR is already in effect

FDA's Quality Management System Regulation took effect on 2 February 2026. QMSR amended Part 820 and incorporates ISO 13485:2016 and Clause 3 of ISO 9000:2015 by reference. FDA law and regulations control if they conflict with the incorporated standards. FDA QMSR page

Current Part 4 treats the device constituent as a finished device under QMSR. A drug-CGMP-based operating system must meet added device requirements. These include design, risk-management records, purchasing and complaint processes. The reverse approach, based on QMSR, adds specified drug CGMP requirements. Use the current text of §§4.2 and 4.4 to select the applicable requirements.

Older section-number checklists are a practical nuisance here. FDA's January 2017 manufacturing guidance predates QMSR. Read its former Quality System Regulation references alongside current Part 4. ISO certification alone is not sufficient evidence of FDA compliance. FDA manufacturing guidance and FDA QMSR page

Safety reporting has its own scope

Subpart B applies to combination-product applicants and constituent-part applicants, rather than everyone involved with a product. It does not cover investigational products. Section 4.102 combines reporting based on application type with additional constituent-related obligations. Device-containing products can trigger malfunction, five-day and correction or removal reporting, as applicable. 21 CFR Part 4, Subpart B

There is no single deadline for every event. Section 4.103 requires specified information sharing between constituent-part applicants within five calendar days. That is not a universal FDA-reporting deadline. Sections 4.102 and 4.104 also contain conditional provisions to avoid duplicate reporting. Do not assume every event requires separate drug and device reports. 21 CFR §§4.102–4.104

Which FDA combination product guidance to use

Choose guidance for the question at hand, then read it with the applicable regulations. These documents address separate tasks. They do not form one combined filing checklist.

Status matters as much as the title. FDA's October 2026 document on essential drug delivery performance characteristics is draft guidance, not for implementation. Do not treat its proposals as final requirements.

How Japan's PMDA malfunction reports differ

Japan's public-report category is narrower than the FDA definition. PMDA publishes suspected device-component malfunctions for combination products approved as pharmaceuticals. Examples include prefilled-syringe injections and injections supplied with dose-adjustable pen injectors. The category does not represent every product that FDA would classify as a combination product. PMDA database introduction

These reports generally reproduce submissions from marketing authorization holders. Publication does not establish that PMDA proved causality. For fatal-outcome cases, PMDA describes a separate reference assessment of the device component's relationship to death, including cases with insufficient information. PMDA reading precautions

The same case can appear more than once through different reporters. Report counts are not incidence rates or a ranking of unsafe products. The reporting year is the year PMDA accepted the report, not necessarily the event year, and later information can lead to corrections. Use these records with PMDA's precautions, rather than importing FDA reporting categories or deadlines. PMDA reading precautions

RegAffairs AI's answer on combination products provides a cited explanation of the FDA definition and drug-device regulation.

Related guides

• 21 CFR 211 requirements for finished pharmaceutical drugs
• 21 CFR 803 medical device reporting duties and FDA deadlines
• FDA PMA explained for medical device regulatory submissions
• FDA product code lookup in the device classification database